Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia

Postgraduate Medicine

Volumn 128, Issue 8, 2016, Pages 747-754

  Ross, Stuart A ^a   Caballero, A Enrique ^b   Del Prato, Stefano ^c   Gallwitz, Baptist ^d   Lewis D’Agostino, Diane ^e   Bailes, Zelie ^f   Thiemann, Sandra ^g   Patel, Sanjay ^f   Woerle, Hans Juergen ^g   von Eynatten, Maximilian ^g  

^a UNIVERSITY OF CALGARY   (Canada)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^f BOEHRINGER INGELHEIM LTD   (United Kingdom)

^g BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

clinical trial; Diabetes mellitus type 2; dipeptidyl peptidase 4 inhibitors; drug therapy combination; linagliptin; metformin

Indexed keywords

CREATININE; HEMOGLOBIN A1C; LINAGLIPTIN; METFORMIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; ETHNICITY; FEMALE; GASTRITIS; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WEIGHT CHANGE; ANCESTRY GROUP; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; GLUCOSE BLOOD LEVEL; KIDNEY FUNCTION TEST; MIDDLE AGED; MULTICENTER STUDY;

ADULT; AGED; BLOOD GLUCOSE; BODY MASS INDEX; CONTINENTAL POPULATION GROUPS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; KIDNEY FUNCTION TESTS; LINAGLIPTIN; MALE; METFORMIN; MIDDLE AGED;

EID: 84989219403     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.1080/00325481.2016.1238280     Document Type: Article

References (26)

1. International Diabetes Federation. IDF diabetes atlas. 7th ed. Brussels (Belgium):International Diabetes Federation; 2015. Available from:http://www.idf.org/diabetesatlas
2. Centers for Disease Control and Prevention. National diabetes fact sheet:national estimates and general information on diabetes and prediabetes in the United States. Atlanta:U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2011.
3. R.A.DeFronzo, R.Eldor, M.Abdul-Ghani Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2013;36(Suppl 2):S127–S138.
4. S.E.Inzucchi, R.M.Bergenstal, J.B.Buse, et al. Management of hyperglycemia in type 2 diabetes:a patient-centered approach:position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–1379.
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.
6. R.R.Holman, S.K.Paul, M.A.Bethel, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589.
7. S.Del Prato, G.Penno, R.Miccoli. Changing the treatment paradigm for type 2 diabetes. Diabetes Care. 2009;32(Suppl 2):S217–S222.
8. I.Raz. Guideline approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2013;36(Suppl 2):S139–S144.
9. A.J.Garber, M.J.Abrahamson, J.I.Barzilay, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013;19:327–336.
10. W.Harper, M.Clement, R.Goldenberg, et al. Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada:pharmacologic management of type 2 diabetes. Can J Diabetes. 2013;37:S61–S68.
11. S.A.Ross, H.D.Tildesley, J.Ashkenas. Barriers to effective insulin treatment:the persistence of poor glycemic control in type 2 diabetes. Curr Med Res Opin. 2011;27(Suppl 3):13–20.
12. J.B.Brown, C.Conner, G.A.Nichols. Secondary failure of metformin monotherapy in clinical practice. Diabetes Care. 2010;33:501–506.
13. G.A.Nichols, C.Conner, J.B.Brown. Initial nonadherence, primary failure and therapeutic success of metformin monotherapy in clinical practice. Curr Med Res Opin. 2010;26:2127–2135.
14. T.Karagiannis, P.Paschos, K.Paletas, et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting:systematic review and meta-analysis. BMJ. 2012;344:e1369.
15. Tradjenta (linagliptin) prescribing information. Ridgefield (CT):Boehringer Ingelheim Pharmaceuticals Inc; 2013.
16. Trajenta (linagliptin). Summary of product characteristics. Ingelheim (Germany):Boehringer Ingelheim International GmbH & Co. KG.; 2013.
17. U.Graefe-Mody, S.Retlich, C.Friedrich. Clinical pharmacokinetics and pharmacodynamics of linagliptin. Clin Pharmacokinet. 2012;51:411–427.
18. S.A.Ross, A.E.Caballero, S.Del Prato, et al. Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia:a randomized, double-blind, active-controlled, parallel group, multinational clinical trial. Diabetes Obes Metab. 2015;17:136–144.
19. S.E.Inzucchi, R.M.Bergenstal, J.B.Buse, et al. Management of hyperglycemia in type 2 diabetes, 2015:a patient-centered approach:update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–149.
20. D.Sherifali, K.Nerenberg, E.Pullenayegum, et al. The effect of oral antidiabetic agents on A1C levels:a systematic review and meta-analysis. Diabetes Care. 2010;33:1859–1864.
21. E.R.Seaquist, J.Anderson, B.Childs, et al. Hypoglycemia and diabetes:a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36:1384–1395.
22. A.Slomski. Avoiding hypoglycemia at all costs is crucial for some with diabetes. JAMA. 2013;309:2536–2537.
23. S.Han, K.Iglay, M.J.Davies, et al. Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens:a meta-analysis. Curr Med Res Opin. 2012;28:969–977.
24. L.Blonde, Z.T.San Juan. Fixed-dose combinations for treatment of type 2 diabetes mellitus. Adv Ther. 2012;29:1–13.
25. V.Hutchins, B.Zhang, R.L.Fleurence, et al. A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin. 2011;27:1157–1168.
26. N.Marx, J.Rosenstock, S.E.Kahn, et al. Design and baseline characteristics of the CARdiovascular outcome trial of LINAgliptin versus glimepiride in type 2 diabetes (CAROLINA®). Diab Vasc Dis Res. 2015;12:164–174.